AbbVie and Capsida Biotherapeutics Inc. have announced an expanded collaboration to develop genetic medicines for high unmet need eye diseases. The partnership will utilize AbbVie's capabilities and Capsida's adeno-associated virus (AAV) engineering platform and manufacturing capability to advance three programs. The collaboration builds upon a previously announced neurodegenerative disease partnership. AbbVie's vice president and global head of discovery research, Jonathon Sedgwick, Ph.D., said the partnership has the potential to develop transformative therapies for patients with serious eye diseases.
Capsida's CEO, Peter Anastasiou, added that combining AbbVie's expertise in eye disease drug development with Capsida's fully integrated next-generation AAV engineering platform offers the potential to provide novel therapies benefiting patients. Under the expanded agreement, Capsida will receive $70 million, with the potential for up to $595 million in option fees and research and development milestones. Capsida is also eligible to receive mid-to-high single-digit royalty payments on future product sales. Capsida will lead capsid discovery efforts for all programs and be responsible for process development and early clinical manufacturing, while AbbVie will lead innovative therapeutic cargo approaches and be responsible for development and commercialization.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!